Abbott Laboratories (NYSE:ABT) Shares Unloaded Rep. Julie Johnson

Representative Julie Johnson (Democratic-Texas) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on June 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on May 12th. The trade occurred in the Representative’s “MERRILL LYNCH TAX EFFICIENT CORE” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Accenture (NYSE:ACN) on 5/12/2026.

Abbott Laboratories Stock Performance

Shares of NYSE:ABT traded up $4.00 during trading on Thursday, hitting $94.48. The company’s stock had a trading volume of 2,613,555 shares, compared to its average volume of 12,125,198. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The firm has a market cap of $164.57 billion, a price-to-earnings ratio of 26.41, a P/E/G ratio of 1.56 and a beta of 0.63. The company has a 50-day moving average of $89.39 and a 200-day moving average of $105.69. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.54.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm’s revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the company earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, sell-side analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.7%. Abbott Laboratories’s dividend payout ratio is presently 70.59%.

Insider Activity

In related news, Director Daniel J. Starks purchased 10,000 shares of Abbott Laboratories stock in a transaction dated Monday, April 27th. The shares were acquired at an average cost of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Philip P. Boudreau purchased 2,200 shares of the firm’s stock in a transaction on Thursday, April 23rd. The shares were purchased at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the purchase, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 0.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Citigroup lowered their price target on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a report on Friday, April 17th. Bank of America reduced their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Evercore dropped their price objective on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Argus reduced their target price on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, April 21st. Finally, Wells Fargo & Company reduced their target price on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $118.30.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott announced a global licensing agreement with ALZpath to advance a blood-based Alzheimer’s disease test on its Alinity ci-series systems, a potentially meaningful long-term growth driver for its diagnostics business. Reuters: ALZpath signs licensing deal with Abbott to develop Alzheimer’s blood test
• Positive Sentiment: Multiple recent articles highlighted Abbott’s strong emerging-markets momentum, especially in established pharmaceuticals, supported by branded generics demand, biosimilar expansion, and new approvals. Yahoo Finance: How Are Emerging Markets Supporting Abbott’s EPD Momentum?
• Positive Sentiment: Wall Street commentary remains constructive, with one recent piece calling Abbott a high-quality dividend aristocrat and another noting strong investor interest and upbeat analyst sentiment, including estimates for meaningful upside. Insider Monkey: How Does Wall Street View Abbott Laboratories (ABT)’s Outlook?
• Neutral Sentiment: Abbott is also being cited as a dependable long-term income stock thanks to its 54-year dividend growth streak and diversified healthcare segments, which reinforces the defensive case but is unlikely to move the shares sharply on its own. 247WallSt: Unstoppable Dividend Aristocrat
• Negative Sentiment: Legal overhang remains a concern after a Missouri appeals court declined to send Abbott’s appeal of the $495 million preterm baby formula verdict to a higher court, keeping litigation risk in focus for investors. MSN: Missouri appeals court won’t send Abbott’s appeal…

Hedge Funds Weigh In On Abbott Laboratories

Several large investors have recently made changes to their positions in ABT. MidAtlantic Capital Management Inc. acquired a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $25,000. Cornerstone Financial Management LLC acquired a new stake in Abbott Laboratories in the fourth quarter valued at approximately $25,000. Purpose Unlimited Inc. purchased a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in shares of Abbott Laboratories during the 4th quarter valued at approximately $26,000. Finally, Abound Financial LLC acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at about $26,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.